...ALK) gene rearrangement who did not respond to crizotinib but subsequently benefited from treatment with ceritinib (LDK3...
CRA7506 Background: The ability to detect driver mutations like EGFR and EML4-ALK in tumor specimens from patients with ...
...ALK and MET/HGF receptor tyrosine kinases. EML4-ALK fusion oncogenes have been reported in approximately 4% of NSCLC. Pa...
...ALK rearrangements, but not affect the overall survival of patients with LAC and EGFR amplification or ALK rearrangement...
...ALK rearrangement in lung cancer, the first-in-class ALK inhibitor (ALKi), crizotinib, was approved for metastatic ALK-r...
...ALK) testing. Next-generation sequencing (NGS) reveals more actionable genomic alterations than do standard diagnostic m...
...ALK, BCR-ABL, BRAF, BTK, and EGFR. A key therapeutic challenge is how to reduce tumor growth after treatment, since this...
...ALK and multiple lymphadenopathy, we diagnosed ALK-positive ALCL forming a solitary skin tumor on the forearm. The patie...
...ALK by immunohistochemistry. A fluorescence in situ hybridization analysis revealed the translocation of a part of the A...
...ALK-positive non-small-cell lung cancer (NSCLC). Patients and Methods Both studies included patients with ALK-positive N...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2026.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
